Faeth Therapeutics, Inc. (FTH) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 17.93M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -198.82M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $17.93M | $-198.82M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $13.71M | $-185.64M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $1.27M | $-22.29M | $32.00K | (m) | (m) | -696.50× | Reported |
| 2025-09-30 | (m) | (m) | $1.37M | $-25.61M | $46.00K | (m) | (m) | -556.63× | Reported |
| 2025-06-30 | (m) | (m) | $1.85M | $-28.58M | $61.00K | (m) | (m) | -468.48× | Reported |
| 2025-03-31 | (m) | (m) | $2.38M | $-31.16M | $75.00K | (m) | (m) | -415.44× | Reported |
| 2024-12-31 | (m) | (m) | $3.13M | $-32.61M | $90.00K | (m) | (m) | -362.38× | Reported |
| 2024-09-30 | (m) | (m) | $3.84M | $-32.48M | $104.00K | (m) | (m) | -312.33× | Reported |
| 2024-06-30 | (m) | (m) | $4.16M | $-32.40M | $116.00K | (m) | (m) | -279.28× | Reported |
| 2024-03-31 | (m) | (m) | $4.46M | $-34.79M | $130.00K | (m) | (m) | -267.58× | Reported |
| 2023-12-31 | (m) | (m) | $4.45M | $-37.06M | $144.00K | (m) | (m) | -257.39× | Reported |
| 2023-09-30 | (m) | (m) | $4.75M | $-41.97M | $-93.00K | (m) | (m) | (m) | Reported |
| 2023-06-30 | (m) | (m) | $5.19M | $-48.17M | $-116.00K | (m) | (m) | (m) | Reported |
| 2023-03-31 | (m) | (m) | $5.51M | $-48.71M | $18.00K | (m) | (m) | -2706.06× | Reported |
| 2022-12-31 | (m) | (m) | $5.81M | $-50.19M | $219.00K | (m) | (m) | -229.17× | Reported |
| 2022-09-30 | (m) | (m) | $5.24M | $-46.55M | $731.00K | (m) | (m) | -63.68× | Reported |
| 2022-06-30 | (m) | (m) | $5.50M | $-42.93M | $935.00K | (m) | (m) | -45.91× | Reported |
| 2022-03-31 | (m) | (m) | $5.82M | $-42.00M | $910.00K | (m) | (m) | -46.15× | Reported |
| 2021-12-31 | (m) | (m) | $5.66M | $-37.48M | $670.00K | (m) | (m) | -55.94× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $1.49M | $-19.45M | $1.69M | (m) | (m) | -11.52× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |